Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2024 | Apr. 26, 2024 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001549084 | |
Entity Registrant Name | EKSO BIONICS HOLDINGS, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2024 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-37854 | |
Entity Incorporation, State or Country Code | NV | |
Entity Tax Identification Number | 99-0367049 | |
Entity Address, Address Line One | 101 Glacier Point, Suite A | |
Entity Address, City or Town | San Rafael | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94901 | |
City Area Code | 510 | |
Local Phone Number | 984-1761 | |
Title of 12(b) Security | Common Stock, $0.001 par value per share | |
Trading Symbol | EKSO | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 18,174,426 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and restricted cash | $ 8,799 | $ 8,638 |
Accounts receivable, net of allowances of $16 and $79, respectively | 5,773 | 5,645 |
Inventories | 5,106 | 5,050 |
Prepaid expenses and other current assets | 838 | 875 |
Total current assets | 20,516 | 20,208 |
Property and equipment, net | 1,862 | 2,018 |
Right-of-use assets | 893 | 977 |
Intangible assets, net | 4,815 | 4,892 |
Goodwill | 431 | 431 |
Other assets | 440 | 392 |
Total assets | 28,957 | 28,918 |
Current liabilities: | ||
Accounts payable | 1,876 | 1,847 |
Accrued liabilities | 1,786 | 2,664 |
Deferred revenues, current | 2,028 | 1,993 |
Note payable, current | 1,250 | 1,250 |
Lease liabilities, current | 372 | 363 |
Total current liabilities | 7,312 | 8,117 |
Deferred revenues | 2,119 | 2,169 |
Notes payable, net | 4,594 | 4,832 |
Lease liabilities | 626 | 723 |
Warrant liabilities | 133 | 366 |
Other non-current liabilities | 122 | 105 |
Total liabilities | 14,906 | 16,312 |
Commitments and contingencies (Note 14) | ||
Stockholders’ equity: | ||
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 141,429 shares authorized; 18,096 and 14,848 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 18 | 15 |
Additional paid-in capital | 256,160 | 251,580 |
Accumulated other comprehensive income | 447 | 156 |
Accumulated deficit | (242,574) | (239,145) |
Total stockholders’ equity | 14,051 | 12,606 |
Total liabilities and stockholders’ equity | $ 28,957 | $ 28,918 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Allowance for doubtful accounts | $ 16 | $ 79 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000 | 10,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 141,429 | 141,429 |
Common stock, issued (in shares) | 18,096 | 14,848 |
Common stock, outstanding (in shares) | 18,096 | 14,848 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | $ 3,756 | $ 4,122 |
Cost of revenue | 1,805 | 2,122 |
Gross profit | 1,951 | 2,000 |
Operating expenses: | ||
Sales and marketing | 1,818 | 2,088 |
Research and development | 1,136 | 1,154 |
General and administrative | 2,253 | 3,206 |
Total operating expenses | 5,207 | 6,448 |
Loss from operations | (3,256) | (4,448) |
Other (expense) income, net: | ||
Interest expense, net | (57) | (112) |
Loss on modification of warrant | (109) | 0 |
Gain (loss) on revaluation of warrant liabilities | 342 | (26) |
Unrealized (loss) gain on foreign exchange | (349) | 217 |
Other income (expense), net | 0 | (20) |
Total other (expense) income, net | (173) | 59 |
Net loss | (3,429) | (4,389) |
Other comprehensive income (loss) | 291 | (194) |
Comprehensive loss | $ (3,138) | $ (4,583) |
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share) | $ (0.2) | $ (0.33) |
Weighted average number of shares outstanding, basic and diluted (in shares) | 17,419 | 13,296 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2022 | 0 | 13,203 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 13 | $ 248,813 | $ 563 | $ (223,947) | $ 25,442 |
Net loss | $ 0 | $ 0 | 0 | 0 | (4,389) | (4,389) |
Equity incentive plan (in shares) | 0 | 139 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 424 | 0 | 0 | 424 |
Foreign currency translation adjustments | $ 0 | $ 0 | 0 | (194) | 0 | (194) |
Balance (in shares) at Mar. 31, 2023 | 0 | 13,342 | ||||
Balance at Mar. 31, 2023 | $ 0 | $ 13 | 249,237 | 369 | (228,336) | 21,283 |
Balance (in shares) at Dec. 31, 2022 | 0 | 13,203 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 13 | $ 248,813 | 563 | (223,947) | 25,442 |
Matching contribution to 401(k) plan (in shares) | 0 | |||||
Balance (in shares) at Dec. 31, 2023 | 0 | 14,848 | ||||
Balance at Dec. 31, 2023 | $ 0 | $ 15 | $ 251,580 | 156 | (239,145) | 12,606 |
Net loss | $ 0 | $ 0 | 0 | 0 | (3,429) | (3,429) |
Equity financing, net (in shares) | 0 | 2,997 | ||||
Equity financing, net | $ 0 | $ 3 | $ 3,967 | 0 | 0 | 3,970 |
Matching contribution to 401(k) plan (in shares) | 0 | 163 | 163 | |||
Matching contribution to 401(k) plan | $ 0 | $ 0 | $ 237 | 0 | 0 | 237 |
Equity incentive plan (in shares) | 0 | 88 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 376 | 0 | 0 | 376 |
Foreign currency translation adjustments | $ 0 | $ 0 | 0 | 291 | 0 | 291 |
Balance (in shares) at Mar. 31, 2024 | 0 | 18,096 | ||||
Balance at Mar. 31, 2024 | $ 0 | $ 18 | $ 256,160 | $ 447 | $ (242,574) | $ 14,051 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating activities: | ||
Net loss | $ (3,429) | $ (4,389) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation and amortization | 406 | 414 |
Changes in provision for credit losses on accounts receivable | (12) | 1 |
(Gain) loss on revaluation of warrant liabilities | (342) | 26 |
Stock-based compensation expense | 376 | 424 |
Loss on modification of warrant | 109 | 0 |
Common stock contribution to 401(k) plan | 29 | 93 |
Unrealized loss (gain) on foreign currency transactions | 349 | (217) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (214) | (202) |
Inventories | (80) | (375) |
Prepaid expenses and other assets, current and noncurrent | 36 | (134) |
Accounts payable | 32 | (110) |
Accrued, lease and other liabilities, current and noncurrent | (723) | (248) |
Deferred revenues | (3) | 503 |
Net cash used in operating activities | (3,466) | (4,214) |
Investing activities: | ||
Acquisition of property and equipment | (8) | (42) |
Net cash used in investing activities | (8) | (42) |
Financing activities: | ||
Principal payments under note payable | (313) | 0 |
Proceeds from issuance of common stock, net | 3,970 | 0 |
Net cash provided by financing activities | 3,657 | 0 |
Effect of exchange rate changes on cash | (22) | 8 |
Net increase (decrease) in cash | 161 | (4,248) |
Cash and restricted cash at beginning of period | 8,638 | 20,525 |
Cash and restricted cash at end of period | 8,799 | 16,277 |
Supplemental disclosure of cash flow activities | ||
Cash paid for interest | 48 | 47 |
Supplemental disclosure of non-cash activities | ||
Transfer of inventory to (from) property and equipment | 16 | (96) |
Share issuance for common stock contribution to 401(k) plan | $ 237 | $ 0 |
Note 1 - Organization
Note 1 - Organization | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Organization Description of Business Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets wearable powered and non-powered exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology is primarily focused on aiding in the recovery and improved quality of life of individuals who have suffered from a variety of neurological conditions and allows for neurorehabilitation ranging from hospital to home, and also has technology that can be utilized by able-bodied users in the workplace. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI") to rehabilitate and to stand and walk in neurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005 , Liquidity and Going Concern As of March 31, 2024 three March 31, 2024 March 31, 2024 As described in Note 9. Notes Payable, net March 31, 2024 March 31, 2024 Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one one no 12 The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies and Estimates | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three March 31, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss. Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250. not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not March 31, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two customers with an accounts receivable balance totaling 10% March 31, 2024 no December 31, 2023 During the three March 31, 2024 10% three March 31, 2023 Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 December 15, 2023, December 15, 2024. Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06 may first 2024 not |
Note 3 - Accumulated Other Comp
Note 3 - Accumulated Other Comprehensive Income (Loss) | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Comprehensive Income (Loss) Note [Text Block] | 3. Accumulated Other Comprehensive Income (Loss) The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 291 (194 ) Balance at end of period $ 447 $ 369 |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurement | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 4. Fair Value Measurement Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two may • Level 1 • Level 2 1 not • Level 3 no 3 The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows: Total Level 1 Level 2 Level 3 March 31, 2024 Liabilities Warrant liabilities $ 133 $ — $ — $ 133 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 three March 31, 2024 Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Net gain on revaluation of warrants issued (342 ) Balance as of March 31, 2024 $ 133 Refer to Note 11. . |
Note 5 - Inventories
Note 5 - Inventories | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 5. Inventories Inventories consisted of the following: March 31, 2024 December 31, 2023 Raw materials $ 3,986 $ 4,298 Work in progress 361 290 Finished goods 759 462 Inventories $ 5,106 $ 5,050 |
Note 6 - Revenue
Note 6 - Revenue | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 6. Revenue The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, along with the sale of support and maintenance contracts. Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements ranging from 12 to 48 months. Revenue is recognized evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over 24 The Company’s industrial device segment (EksoWorks) revenue is primarily generated through the sale of the upper body exoskeleton EVO and associated accessories. Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility. Deferred Revenue Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. Deferred revenue consisted of the following: March 31, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,915 3,993 Deferred device and advances 232 169 Total deferred revenues 4,147 4,162 Less current portion (2,028 ) (1,993 ) Deferred revenues, non-current $ 2,119 $ 2,169 On September 25, 2023, Deferred revenue activity consisted of the following for the three March 31, 2024 Beginning balance $ 4,162 Deferral of revenue 684 Recognition of deferred revenue (699 ) Ending balance $ 4,147 The Company expects to recognize approximately $1,662 of the deferred revenue during the remainder of 2024 2025 thereafter In addition to deferred revenue, the Company has a non-cancellable backlog of $1,946, expected to be recognized between 2024 2026, not 24 Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source for the three March 31, 2024 EksoHealth EksoWorks Total Device revenue $ 2,585 $ 168 $ 2,753 Service and support 765 — 765 Subscriptions 144 — 144 Parts and other 65 29 94 $ 3,559 $ 197 $ 3,756 The following table disaggregates the Company’s revenue by major source for the three March 31, 2023 EksoHealth EksoWorks Total Device revenue $ 3,048 $ 111 $ 3,159 Service and support 644 — 644 Subscriptions 275 7 282 Parts and other 30 7 37 $ 3,997 $ 125 $ 4,122 |
Note 7 - Accrued Liabilities
Note 7 - Accrued Liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 7. Accrued Liabilities Accrued liabilities consisted of the following: March 31, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,275 $ 2,058 Device warranty 404 461 Other 107 145 Total $ 1,786 $ 2,664 Warranty The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three March 31, 2024 Three Months Ended March 31, 2024 Balance at beginning of the period $ 566 Additions for estimated future expense 121 Incurred costs (161 ) Balance at end of the period $ 526 Balance as of March 31, 2024 Current portion $ 404 Long-term portion 122 Total $ 526 |
Note 8 - Goodwill and Intangibl
Note 8 - Goodwill and Intangible Assets | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 8. Goodwill and Intangible Assets On December 5, 2022, Goodwill The Company accounted for the acquisition as a business combination in accordance with ASC 805, The Company determined no three March 31, 2024 Intangible Assets The following table summarizes the components of gross assets, accumulated amortization, and net carrying values for definite and indefinite lived intangible asset balances as of March 31, 2024 March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (382 ) $ 1,928 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (23 ) 117 Below market lease 20 (20 ) — Total intangible assets $ 5,240 $ (425 ) $ 4,815 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Below market lease 20 (20 ) — Total intangible assets $ 5,240 $ (348 ) $ 4,892 Definite lived intangible assets are amortized over their estimated lives using the straight line method, which is estimated as eight 12 eight one no no three March 31, 2024 The estimated future amortization expenses related to definite lived intangible assets as of March 31, 2024 Fiscal Year Amount 2024 - remainder $ 230 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 895 Total $ 2,505 Amortization expense related to the acquired definite lived intangible assets was $77 and $82 for the three March 31, 2024 2023, |
Note 9 - Notes Payable, Net
Note 9 - Notes Payable, Net | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Long-Term Debt [Text Block] | 9. Notes Payable, net PWB Term Loan In August 2020, first The Company was required to pay accrued interest on the current loan on the 13th August 13, 2023, August 17, 2023, August 13, 2026 470, The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain cash in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of March 31, 2024 March 31, 2024 The interest rate of the PWB Term Loan is subject to increase in the event of late payment and after occurrence of and during the continuation of an event of default. The Company may The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 8.74% for the three March 31, 2024 three March 31, 2024 2023, The following table presents scheduled principal payments of the Company’s PWB term loan as of March 31, 2024 Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (6 ) Note payable, net $ 1,994 Current portion $ — Long-term portion 1,994 Note payable, net $ 1,994 Parker Hannifin Promissory Note In connection with the HMC Acquisition, on December 5, 2022, December 31, 2023 September 30, 2027. The Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a) 5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity. The Company recorded the Promissory Note of $4,055 in its condensed consolidated balance sheets under the captions Notes Payable, Current and Notes Payable, Net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's PWB Term Loan and other relevant economic factors present at the execution date of the Promissory Note. The amortization of debt discounts resulted in an effective interest rate of 7.11% for the three March 31, 2024 three March 31, 2024 2023, The following table presents scheduled principal payments of the Company's Promissory Note as of March 31, 2024 Period Amount 2024 - remainder $ 938 2025 1,250 2026 1,250 2027 937 Total principal payments 4,375 Less debt discount (525 ) Note payable, net $ 3,850 Current portion 1,250 Long-term portion 2,600 Note payable, net $ 3,850 |
Note 10 - Lease Obligations
Note 10 - Lease Obligations | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 10. Lease Obligations The Company's operating lease agreement for its headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") commenced in July 2022 October 2026 three The Company has determined that the new San Rafael Lease constitutes an operating lease under ASC 842 July 2022 October 2026. three The Company's operating lease agreement for its office in Hamburg, Germany commenced in May 2022 June 2025 one five The Company has determined that the new Hamburg lease agreement constitutes a lease under ASC 842 May 2022 June 2025. five The Company’s future lease payments as of March 31, 2024 Periods Operating Leases 2024 - remainder $ 328 2025 416 2026 362 Total lease payments 1,106 Less: imputed interest (108 ) Present value of lease liabilities $ 998 Weighted-average remaining lease term (in years) 2.48 Weighted-average discount rate 8.2 % Lease expense under the Company’s operating leases was $136 and $133 for the three March 31, 2024 2023 |
Note 11 - Capitalization and Eq
Note 11 - Capitalization and Equity Structure | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Equity [Text Block] | 11. Capitalization and Equity Structure Summary The Company’s authorized capital stock at March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 14,848 January 2024 On January 10, 2024, “January 2024 January 2024 January 2024 At the Market Offering In October 2020, may may June 2023, may not three March 31, 2024, not three March 31, 2023. March 31, 2024, Warrants Warrants outstanding as of March 31, 2024 December 31, 2023 Exercise Remaining term Source Price (Years) December 31, 2023 Issued Exercised March 31, 2024 2021 Warrants $ 12.81 1.9 273 — — 273 June 2020 Investor Warrants $ 5.18 1.7 127 — — 127 June 2020 Placement Agent Warrants $ 5.64 1.2 39 — — 39 December 2019 Warrants $ 8.10 1.2 556 — — 556 December 2019 Placement Agent Warrants $ 8.44 0.7 52 — — 52 May 2019 Warrants $ 1.55 0.1 193 — — 193 1,240 — — 1,240 No warrants were exercised during the three three March 31, 2024 2023 2021 In February 2021, "2021 2021 five February 11, 2026. In addition, the 2021 2021 2021 not may 2021 2021 2021 The 2021 2021 2021 30 2021 2021 five 2021 The warrant liability related to the 2021 3 2021 March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.65 % 4.20 % Expected term (years) 1.86 2.11 Volatility of stock 94.2 % 76.5 % June 2020 In June 2020, "June 2020 June 2020 five one December 10, 2025. In addition, the June 2020 June 2020 June 2020 not may June 2020 June 2020 The June 2020 The June 2020 June 2020 June 2020 June 2020 June 2020 June 2020 30 June 2020 June 2020 June 2020 The warrant liability related to the June 2020 3 June 2020 March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.73 % 4.26 % Expected term (years) 1.69 1.94 Volatility of stock 95.4 % 78.2 % June 2020 In June 2020, "June 2020 June 2020 June 2020 June 7, 2025. Because of the put-option provision in the June 2020 The warrant liability related to the June 2020 3 June 2020 March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 4.95 % 4.54 % Expected term (years) 1.19 1.44 Volatility of stock 102.1 % 83.0 % December 2019 In December 2019, "December 2019 "December 2019 December 2019 five June 21, 2025. The December 2019 December 2019 December 2019 December 2019 December 2019 30 December 2019 December 2019 five December 2019 The warrant liability related to the December 2019 3 December 2019 March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 4.93 % 4.53 % Expected term (years) 1.22 1.47 Volatility of stock 101.3 % 82.3 % December 2019 In December 2019, December 2019 "December 2019 December 2019 December 2019 December 18, 2025. The warrant liability related to the December 2019 3 December 2019 March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.23 % 4.82 % Expected term (years) 0.72 0.97 Volatility of stock 123.4 % 85.2 % Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 December 2019 May 2019 In May 2019, "May 2019 "May 2019 May 2019 five May 24, 2024. May 2019 May 2019 May 2019 may January 2024 May 2019 In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may May 2019 may, The May 2019 May 2019 May 2019 2019 90 May 2019 two May 2019 The warrant liability related to the May 2019 3 May 2019 May 2019 March 31, 2024 December 31, 2023 Share price $ 1.36 $ 1.88 (1) Conversion price $ 1.55 $ 3.52 Risk-free interest rate 5.48 % 5.3 % Expected term (years) 0.1 0.4 Volatility of stock 92.2 % 77.5 % ( 1 December 31, 2023, first 2024, 25% Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 |
Note 12 - Stock-based Compensat
Note 12 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 12. Stock-based Compensation The Company's Amended and Restated 2014 "2014 January 31, 2024. no may 2014 not Stock Options The following table summarizes information about the Company’s stock options outstanding as of March 31, 2024 three Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (55 ) 37.54 Balance as of March 31, 2024 197 $ 37.79 4.26 $ — Vested and expected to vest as of March 31, 2024 197 $ 37.79 4.26 $ — Exercisable as of March 31, 2024 196 $ 37.80 4.26 $ — There were no stock options awarded during the three March 31, 2024 2023 March 31, 2024. Restricted Stock Units The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employee members of the Board. Each RSU and PSU represents the right to receive one Combined RSU and PSU activity for the three March 31, 2024 Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Vested (172 ) 1.87 Unvested as of March 31, 2024 1,133 $ 1.64 As of March 31, 2024 Compensation Expense Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to options, RSUs and PSUs was recorded as follows: Three Months Ended March 31, 2024 2023 Sales and marketing $ 52 $ 64 Research and development 91 82 General and administrative 233 278 $ 376 $ 424 401 During the three March 31, 2024 401 December 31, 2023 No 401 three March 31, 2023. The expense for the 401 three March 31, 2024 2023 |
Note 13 - Income Taxes
Note 13 - Income Taxes | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 13. Income Taxes There were no three March 31, 2024 not |
Note 14 - Commitments and Conti
Note 14 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 14. Commitments and Contingencies Material Contracts The Company has two In connection with the HMC Acquisition, the Company assumed two The Vanderbilt Exoskeleton License Agreement was entered into as of October 15, 2012 April 29, 2038, The Vanderbilt Knee License Agreement was entered into as of March 1, 2022 February 15, 2041, July 31, 2028 The Company also entered into transitional use agreements with Parker granting the Company access to certain information technology systems and shared services relating to manufacturing facilities in Macedonia, Ohio for twelve December 2023. not May 2024, 18 twelve May 2024. Purchase Obligations The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $2,387 as of March 31, 2024 one December 31, 2023 may The Company has operating lease commitments totaling $1,106 payable over 32 months related to the San Rafael, California and Hamburg, Germany leases disclosed in Note 10. Loss Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not |
Note 15 - Net Loss Per Share
Note 15 - Net Loss Per Share | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share: Three Months Ended March 31, 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (3,429 ) $ (4,389 ) Denominator: Weighted-average number of shares, basic and diluted 17,419 13,296 Net loss per share, basic and diluted $ (0.20 ) $ (0.33 ) The following table sets forth potential shares of common stock that are not Three Months Ended March 31, 2024 2023 Options to purchase common stock 197 268 Restricted stock units 1,133 1,029 Warrants for common stock 1,240 1,240 Total common stock equivalents 2,570 2,537 |
Note 16 - Segment Disclosures
Note 16 - Segment Disclosures | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 16. Segment Disclosures The Company has two The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not not Segment reporting information is as follows: EksoHealth EksoWorks Total Three months ended March 31, 2024 Revenue $ 3,559 $ 197 $ 3,756 Cost of revenue 1,655 150 1,805 Gross profit $ 1,904 $ 47 $ 1,951 Three months ended March 31, 2023 Revenue $ 3,997 $ 125 $ 4,122 Cost of revenue 1,951 171 2,122 Gross profit $ 2,046 $ (46 ) $ 2,000 The Company operates in the following regions: ( 1 2 3 10% three three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Americas United States $ 2,297 $ 2,958 Other 32 4 Americas revenue 2,329 2,962 EMEA France 346 — Germany 124 244 Other 360 512 EMEA revenue 830 756 APAC Indonesia 336 — Other 261 404 APAC revenue 597 404 Total Revenue $ 3,756 $ 4,122 |
Note 17 - Related Party Transac
Note 17 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 17. Related Party Transactions On February 4, 2023, July 2017. one two The Company's total settlement amount was $325 and to be paid in cash over fourteen first twelve March 31, 2024 December 31, 2023 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 5. During the quarter ended March 31, 2024, no 16a 1 10b5 1 10b5 1 408. |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three March 31, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss. |
Inventory, Policy [Policy Text Block] | Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first |
Lessee, Leases [Policy Text Block] | Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not |
Revenue [Policy Text Block] | Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250. not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not March 31, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two customers with an accounts receivable balance totaling 10% March 31, 2024 no December 31, 2023 During the three March 31, 2024 10% three March 31, 2023 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 December 15, 2023, December 15, 2024. Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06 may first 2024 not |
Note 3 - Accumulated Other Co_2
Note 3 - Accumulated Other Comprehensive Income (Loss) (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Three Months Ended March 31, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 291 (194 ) Balance at end of period $ 447 $ 369 |
Note 4 - Fair Value Measureme_2
Note 4 - Fair Value Measurement (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Total Level 1 Level 2 Level 3 March 31, 2024 Liabilities Warrant liabilities $ 133 $ — $ — $ 133 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Net gain on revaluation of warrants issued (342 ) Balance as of March 31, 2024 $ 133 |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, 2024 December 31, 2023 Raw materials $ 3,986 $ 4,298 Work in progress 361 290 Finished goods 759 462 Inventories $ 5,106 $ 5,050 |
Note 6 - Revenue (Tables)
Note 6 - Revenue (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | March 31, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,915 3,993 Deferred device and advances 232 169 Total deferred revenues 4,147 4,162 Less current portion (2,028 ) (1,993 ) Deferred revenues, non-current $ 2,119 $ 2,169 Beginning balance $ 4,162 Deferral of revenue 684 Recognition of deferred revenue (699 ) Ending balance $ 4,147 |
Disaggregation of Revenue [Table Text Block] | EksoHealth EksoWorks Total Device revenue $ 2,585 $ 168 $ 2,753 Service and support 765 — 765 Subscriptions 144 — 144 Parts and other 65 29 94 $ 3,559 $ 197 $ 3,756 EksoHealth EksoWorks Total Device revenue $ 3,048 $ 111 $ 3,159 Service and support 644 — 644 Subscriptions 275 7 282 Parts and other 30 7 37 $ 3,997 $ 125 $ 4,122 |
Note 7 - Accrued Liabilities (T
Note 7 - Accrued Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | March 31, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,275 $ 2,058 Device warranty 404 461 Other 107 145 Total $ 1,786 $ 2,664 |
Product Maintenance And Warranty [Table Text Block] | Three Months Ended March 31, 2024 Balance at beginning of the period $ 566 Additions for estimated future expense 121 Incurred costs (161 ) Balance at end of the period $ 526 Balance as of March 31, 2024 Current portion $ 404 Long-term portion 122 Total $ 526 |
Note 8 - Goodwill and Intangi_2
Note 8 - Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (382 ) $ 1,928 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (23 ) 117 Below market lease 20 (20 ) — Total intangible assets $ 5,240 $ (425 ) $ 4,815 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Below market lease 20 (20 ) — Total intangible assets $ 5,240 $ (348 ) $ 4,892 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Fiscal Year Amount 2024 - remainder $ 230 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 895 Total $ 2,505 |
Note 9 - Notes Payable, Net (Ta
Note 9 - Notes Payable, Net (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Maturities of Long-Term Debt [Table Text Block] | Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (6 ) Note payable, net $ 1,994 Current portion $ — Long-term portion 1,994 Note payable, net $ 1,994 Period Amount 2024 - remainder $ 938 2025 1,250 2026 1,250 2027 937 Total principal payments 4,375 Less debt discount (525 ) Note payable, net $ 3,850 Current portion 1,250 Long-term portion 2,600 Note payable, net $ 3,850 |
Note 10 - Lease Obligations (Ta
Note 10 - Lease Obligations (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Periods Operating Leases 2024 - remainder $ 328 2025 416 2026 362 Total lease payments 1,106 Less: imputed interest (108 ) Present value of lease liabilities $ 998 Weighted-average remaining lease term (in years) 2.48 Weighted-average discount rate 8.2 % |
Note 11 - Capitalization and _2
Note 11 - Capitalization and Equity Structure (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Exercise Remaining term Source Price (Years) December 31, 2023 Issued Exercised March 31, 2024 2021 Warrants $ 12.81 1.9 273 — — 273 June 2020 Investor Warrants $ 5.18 1.7 127 — — 127 June 2020 Placement Agent Warrants $ 5.64 1.2 39 — — 39 December 2019 Warrants $ 8.10 1.2 556 — — 556 December 2019 Placement Agent Warrants $ 8.44 0.7 52 — — 52 May 2019 Warrants $ 1.55 0.1 193 — — 193 1,240 — — 1,240 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.65 % 4.20 % Expected term (years) 1.86 2.11 Volatility of stock 94.2 % 76.5 % March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.73 % 4.26 % Expected term (years) 1.69 1.94 Volatility of stock 95.4 % 78.2 % March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 4.95 % 4.54 % Expected term (years) 1.19 1.44 Volatility of stock 102.1 % 83.0 % March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 4.93 % 4.53 % Expected term (years) 1.22 1.47 Volatility of stock 101.3 % 82.3 % March 31, 2024 December 31, 2023 Current share price $ 1.36 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.23 % 4.82 % Expected term (years) 0.72 0.97 Volatility of stock 123.4 % 85.2 % March 31, 2024 December 31, 2023 Share price $ 1.36 $ 1.88 (1) Conversion price $ 1.55 $ 3.52 Risk-free interest rate 5.48 % 5.3 % Expected term (years) 0.1 0.4 Volatility of stock 92.2 % 77.5 % |
Note 12 - Stock-based Compens_2
Note 12 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (55 ) 37.54 Balance as of March 31, 2024 197 $ 37.79 4.26 $ — Vested and expected to vest as of March 31, 2024 197 $ 37.79 4.26 $ — Exercisable as of March 31, 2024 196 $ 37.80 4.26 $ — |
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] | Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Vested (172 ) 1.87 Unvested as of March 31, 2024 1,133 $ 1.64 |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, 2024 2023 Sales and marketing $ 52 $ 64 Research and development 91 82 General and administrative 233 278 $ 376 $ 424 |
Note 15 - Net Loss Per Share (T
Note 15 - Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (3,429 ) $ (4,389 ) Denominator: Weighted-average number of shares, basic and diluted 17,419 13,296 Net loss per share, basic and diluted $ (0.20 ) $ (0.33 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2024 2023 Options to purchase common stock 197 268 Restricted stock units 1,133 1,029 Warrants for common stock 1,240 1,240 Total common stock equivalents 2,570 2,537 |
Note 16 - Segment Disclosures (
Note 16 - Segment Disclosures (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | EksoHealth EksoWorks Total Three months ended March 31, 2024 Revenue $ 3,559 $ 197 $ 3,756 Cost of revenue 1,655 150 1,805 Gross profit $ 1,904 $ 47 $ 1,951 Three months ended March 31, 2023 Revenue $ 3,997 $ 125 $ 4,122 Cost of revenue 1,951 171 2,122 Gross profit $ 2,046 $ (46 ) $ 2,000 |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended March 31, 2024 2023 Americas United States $ 2,297 $ 2,958 Other 32 4 Americas revenue 2,329 2,962 EMEA France 346 — Germany 124 244 Other 360 512 EMEA revenue 830 756 APAC Indonesia 336 — Other 261 404 APAC revenue 597 404 Total Revenue $ 3,756 $ 4,122 |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Retained Earnings (Accumulated Deficit) | $ (242,574) | $ (239,145) | |
Net Cash Provided by (Used in) Operating Activities | (3,466) | $ (4,214) | |
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | 8,799 | ||
Debt Covenant, Covenant Compliance, Unrestricted Cash | 2,000 | ||
Unrestricted Cash | $ 6,799 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies and Estimates (Details Textual) - Customer Concentration Risk [Member] | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Accounts Receivable [Member] | ||
Number Of Customers | 2 | |
Accounts Receivable [Member] | Customer A [Member] | ||
Concentration Risk, Percentage | 11% | |
Accounts Receivable [Member] | Customer B [Member] | ||
Concentration Risk, Percentage | 11% | |
Revenue from Contract with Customer Benchmark [Member] | ||
Number Of Customers | 1 | 2 |
Revenue from Contract with Customer Benchmark [Member] | Customer A [Member] | ||
Concentration Risk, Percentage | 11% | 26% |
Revenue from Contract with Customer Benchmark [Member] | Customer B [Member] | ||
Concentration Risk, Percentage | 14% |
Note 3 - Accumulated Other Co_3
Note 3 - Accumulated Other Comprehensive Income (Loss) - Disclosure of Changes in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Balance | $ 12,606 | $ 25,442 |
Net unrealized gain (loss) on foreign currency translation | 291 | (194) |
Balance | 14,051 | 21,283 |
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||
Balance | 156 | 563 |
Balance | $ 447 | $ 369 |
Note 4 - Fair Value Measureme_3
Note 4 - Fair Value Measurement - Fair Value Hierarchies (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Warrant liabilities | $ 133 | $ 366 |
Fair Value, Inputs, Level 1 [Member] | ||
Warrant liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Warrant liabilities | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Warrant liabilities | $ 133 | $ 366 |
Note 4 - Fair Value Measureme_4
Note 4 - Fair Value Measurement - Changes in Fair Value (Details) - Derivative Financial Instruments, Liabilities [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Balance | $ 366 |
Loss on modification of warrant | 109 |
Net gain on revaluation of warrants issued | (342) |
Balance | $ 133 |
Note 5 - Inventories - Inventor
Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Raw materials | $ 3,986 | $ 4,298 |
Work in progress | 361 | 290 |
Finished goods | 759 | 462 |
Inventories | $ 5,106 | $ 5,050 |
Note 6 - Revenue 1 (Details Tex
Note 6 - Revenue 1 (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Sep. 25, 2023 | |
Contract With Customer, Liability, Non-Cancellable Backlog | $ 1,946 | |
Lessor, Operating Lease, Term of Contract (Month) | 24 months | |
Parker [Member] | ||
Deferred Revenue, Warranty Claim Lump Sum | $ 700 | |
Minimum [Member] | Ekso Health [Member] | ||
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month) | 12 months | |
Maximum [Member] | Ekso Health [Member] | ||
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month) | 48 months |
Note 6 - Revenue 2 (Details Tex
Note 6 - Revenue 2 (Details Textual) $ in Thousands | Mar. 31, 2024 USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,662 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,241 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,244 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Note 6 - Revenue - Deferred Rev
Note 6 - Revenue - Deferred Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Deferred extended maintenance and support | $ 3,915 | $ 3,993 |
Deferred device and advances | 232 | 169 |
Total deferred revenues | 4,147 | 4,162 |
Less current portion | (2,028) | (1,993) |
Deferred revenues, non-current | 2,119 | $ 2,169 |
Beginning balance | 4,162 | |
Deferral of revenue | 684 | |
Recognition of deferred revenue | (699) | |
Ending balance | $ 4,147 |
Note 6 - Revenue - Disaggregati
Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | $ 3,756 | $ 4,122 |
Ekso Health [Member] | ||
Revenue | 3,559 | 3,997 |
Ekso Works [Member] | ||
Revenue | 197 | 125 |
Product [Member] | ||
Revenue | 2,753 | 3,159 |
Product [Member] | Ekso Health [Member] | ||
Revenue | 2,585 | 3,048 |
Product [Member] | Ekso Works [Member] | ||
Revenue | 168 | 111 |
Service [Member] | ||
Revenue | 765 | 644 |
Service [Member] | Ekso Health [Member] | ||
Revenue | 765 | 644 |
Service [Member] | Ekso Works [Member] | ||
Revenue | 0 | 0 |
Subscription [Member] | ||
Revenue | 144 | 282 |
Subscription [Member] | Ekso Health [Member] | ||
Revenue | 144 | 275 |
Subscription [Member] | Ekso Works [Member] | ||
Revenue | 0 | 7 |
Product and Service, Other [Member] | ||
Revenue | 94 | 37 |
Product and Service, Other [Member] | Ekso Health [Member] | ||
Revenue | 65 | 30 |
Product and Service, Other [Member] | Ekso Works [Member] | ||
Revenue | $ 29 | $ 7 |
Note 7 - Accrued Liabilities -
Note 7 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Salaries, benefits and related expenses | $ 1,275 | $ 2,058 |
Device warranty | 404 | 461 |
Other | 107 | 145 |
Total | $ 1,786 | $ 2,664 |
Note 7 - Accrued Liabilities _2
Note 7 - Accrued Liabilities - Warrant Liability (Details) - Warranty [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Balance at beginning of the period | $ 566 |
Additions for estimated future expense | 121 |
Incurred costs | (161) |
Balance at end of the period | 526 |
Current portion | 404 |
Long-term portion | 122 |
Total | $ 526 |
Note 8 - Goodwill and Intangi_3
Note 8 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Goodwill | $ 431 | $ 431 | |
Below Market Lease, Amortization Period (Year) | 1 year | ||
Acquired Finite-Lived Intangible Asset, Amortization | $ 77 | $ 82 | |
Developed Technology Rights [Member] | |||
Finite-Lived Intangible Asset, Useful Life (Year) | 8 years | ||
Intellectual Property [Member] | |||
Finite-Lived Intangible Asset, Useful Life (Year) | 12 years | ||
Customer Relationships [Member] | |||
Finite-Lived Intangible Asset, Useful Life (Year) | 8 years |
Note 8 - Goodwill and Intangi_4
Note 8 - Goodwill and Intangible Assets - Goodwill and Intangible Assets Balances (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Intangibles, Accumulated Amortization | $ (425) | $ (348) |
Intangibles, Net Carrying Amount | 2,505 | |
Intangibles, Gross Carrying Amount | 20 | 20 |
Intangibles, Accumulated Amortization | (20) | (20) |
Intangibles, Net Carrying Amount | 0 | 0 |
Intangibles, Gross Carrying Amount | 5,240 | 5,240 |
Intangibles, Net Carrying Amount | 4,815 | 4,892 |
Trade Names [Member] | ||
Intangibles, Gross Carrying Amount | 2,310 | 2,310 |
Developed Technology Rights [Member] | ||
Intangibles, Gross Carrying Amount | 2,310 | 2,310 |
Intangibles, Accumulated Amortization | (382) | (310) |
Intangibles, Net Carrying Amount | 1,928 | 2,000 |
Intellectual Property [Member] | ||
Intangibles, Gross Carrying Amount | 460 | 460 |
Intangibles, Accumulated Amortization | 0 | 0 |
Intangibles, Net Carrying Amount | 460 | 460 |
Customer Relationships [Member] | ||
Intangibles, Gross Carrying Amount | 140 | 140 |
Intangibles, Accumulated Amortization | (23) | (18) |
Intangibles, Net Carrying Amount | $ 117 | $ 122 |
Note 8 - Goodwill and Intangi_5
Note 8 - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
2024 - remainder | $ 230 |
2025 | 345 |
2026 | 345 |
2027 | 345 |
2028 | 345 |
2029 and thereafter | 895 |
Total | $ 2,505 |
Note 9 - Notes Payable, Net (De
Note 9 - Notes Payable, Net (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | ||
Dec. 05, 2022 | Aug. 30, 2020 | Mar. 31, 2024 | Mar. 31, 2023 | |
Term Loan [Member] | PWB Agreement [Member] | ||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,000 | |||
Debt Instrument, Basis Spread on Variable Rate | 0.50% | |||
Debt Instrument, Interest Rate, Stated Percentage | 4.50% | |||
Long-Term Debt, Gross | $ 2,000 | |||
Debt Instrument, Covenant Compliance, Maximum Deposits Outside Of United States | $ 1,000 | |||
Line of Credit Facility, Interest Rate During Period | 8.74% | |||
Interest Expense, Debt | $ 44 | $ 43 | ||
Subordinated Debt [Member] | Promissory Note [Member] | ||||
Debt Instrument, Basis Spread on Variable Rate | 5% | |||
Debt Instrument, Interest Rate, Stated Percentage | 0% | |||
Long-Term Debt, Gross | $ 4,375 | |||
Line of Credit Facility, Interest Rate During Period | 7.11% | |||
Interest Expense, Debt | $ 75 | $ 79 | ||
Debt Instrument, Face Amount | $ 5,000 | |||
Debt Instrument, Periodic Payment, Number of Installments | 16 | |||
Subordinated Debt | $ 4,055 | |||
Debt Instrument, Discount Rate, Percentage | 7.50% |
Note 9 - Notes Payable, Net - S
Note 9 - Notes Payable, Net - Schedule of Principle Payments (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
Term Loan [Member] | PWB Agreement [Member] | |
2024-2025 | $ 0 |
2026 | 2,000 |
Long-Term Debt, Gross | 2,000 |
Less debt discount and issuance cost | (6) |
Note payable, net | 1,994 |
Current portion | 0 |
Long-term portion | 1,994 |
2026 | 2,000 |
Total principal payments | 2,000 |
Note payable, net | 1,994 |
Current portion | 0 |
Long-term portion | 1,994 |
Subordinated Debt [Member] | Promissory Note [Member] | |
2026 | 1,250 |
Long-Term Debt, Gross | 4,375 |
Note payable, net | 3,850 |
Current portion | 1,250 |
Long-term portion | 2,600 |
2024 - remainder | 938 |
2025 | 1,250 |
2026 | 1,250 |
2027 | 937 |
Total principal payments | 4,375 |
Less debt discount | 525 |
Note payable, net | 3,850 |
Current portion | 1,250 |
Long-term portion | $ 2,600 |
Note 10 - Lease Obligations (De
Note 10 - Lease Obligations (Details Textual) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Jul. 31, 2022 | Feb. 28, 2022 | |
Operating Lease, Expense | $ 136 | $ 133 | ||
San Rafael California [Member] | ||||
Lessee, Operating Lease, Renewal Term (Year) | 3 years | 3 years | ||
Hamburg Germany [Member] | ||||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | |||
Lessee Operating Lease, Number of Extension | 1 |
Note 10 - Lease Obligations - S
Note 10 - Lease Obligations - Schedule of Future Lease Liabilities (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
2024 - remainder | $ 328 |
2025 | 416 |
2026 | 362 |
Lessee, Operating Lease, Liability, to be Paid | 1,106 |
Less: imputed interest | (108) |
Present value of lease liabilities | $ 998 |
Weighted-average remaining lease term (in years) (Year) | 2 years 5 months 23 days |
Weighted-average discount rate | 8.20% |
Note 11 - Capitalization and _3
Note 11 - Capitalization and Equity Structure (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 1 Months Ended | 3 Months Ended | ||||||||
Jan. 10, 2024 | Feb. 28, 2021 | Oct. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | |
Common Stock, Shares Authorized (in shares) | 141,429 | 141,429 | ||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000 | 10,000 | ||||||||
Common Stock, Shares, Outstanding (in shares) | 18,096 | 14,848 | ||||||||
Preferred Stock, Shares Outstanding (in shares) | 0 | 0 | ||||||||
Proceeds from Issuance of Common Stock | $ 3,970 | $ 0 | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 5,000 | |||||||||
Class Of Warrant Or Warrants Exercised (in shares) | 0 | 0 | ||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | |||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,240 | 1,240 | ||||||||
Common Stock, Shares, Issued (in shares) | 18,096 | 14,848 | ||||||||
Preferred Stock, Shares Issued (in shares) | 0 | 0 | ||||||||
A2021 Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 273 | 0 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 12.81 | $ 12.81 | ||||||||
Class of Warrant or Right Expiration Period (Year) | 5 years | |||||||||
Class of Warrant or Right, Outstanding (in shares) | 273 | 273 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 10 months 24 days | |||||||||
June 2020 Investor Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.18 | $ 5.18 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 874 | 127 | 127 | |||||||
Class of Warrant or Right Expiration Period (Year) | 5 years 6 months | |||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 8 months 12 days | |||||||||
June 2020 Placement Agent Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 122 | 0 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.64 | $ 5.64 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 39 | 39 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 2 months 12 days | |||||||||
December 2019 Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.1 | $ 8.1 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 556 | 556 | 556 | |||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 2 months 12 days | 5 years | ||||||||
December 2019 Placement Agent Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.44 | $ 8.44 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 52 | 52 | 52 | |||||||
Warrants and Rights Outstanding, Term (Year) | 8 months 12 days | |||||||||
May 2019 Warrants [Member] | ||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 193 | 193 | 444 | |||||||
Warrants and Rights Outstanding, Term (Year) | 1 month 6 days | 5 years | ||||||||
January 2024 Offering [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,968 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.55 | |||||||||
Proceeds from Issuance of Common Stock | $ 3,931 | |||||||||
At the Market Offering [Member] | ||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.45 | |||||||||
Proceeds from Issuance of Common Stock | $ 39 | |||||||||
Sale of Stock, Price Per Share (in dollars per share) | $ 6.75 | |||||||||
Sale of Stock, Number of Shares Issued in Transaction (in shares) | 30 | 0 | ||||||||
Sale Of Stock, Stock Available For Issuance, Value | $ 4,241 |
Note 11 - Capitalization and _4
Note 11 - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details) - $ / shares shares in Thousands | 1 Months Ended | 3 Months Ended | ||||
Feb. 28, 2021 | Jun. 30, 2020 | Mar. 31, 2024 | Dec. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | |
Balance (in shares) | 1,240 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 1,240 | |||||
A2021 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 12.81 | $ 12.81 | ||||
Term (Year) | 1 year 10 months 24 days | |||||
Balance (in shares) | 273 | |||||
Warrants issued (in shares) | 273 | 0 | ||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 273 | |||||
June 2020 Investor Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 5.18 | $ 5.18 | ||||
Term (Year) | 1 year 8 months 12 days | |||||
Balance (in shares) | 127 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 874 | 127 | ||||
June 2020 Placement Agent Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 5.64 | $ 5.64 | ||||
Term (Year) | 1 year 2 months 12 days | |||||
Balance (in shares) | 39 | |||||
Warrants issued (in shares) | 122 | 0 | ||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 39 | |||||
December 2019 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 8.1 | $ 8.1 | ||||
Term (Year) | 1 year 2 months 12 days | 5 years | ||||
Balance (in shares) | 556 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 556 | |||||
December 2019 Placement Agent Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 8.44 | $ 8.44 | ||||
Term (Year) | 8 months 12 days | |||||
Balance (in shares) | 52 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 52 | |||||
May 2019 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 1.55 | $ 1.55 | ||||
Term (Year) | 1 month 6 days | 5 years | ||||
Balance (in shares) | 193 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 193 |
Note 11 - Capitalization and _5
Note 11 - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details) | Mar. 31, 2024 | Dec. 31, 2023 | |
Measurement Input, Share Price [Member] | May 2019 Warrants [Member] | |||
Warrant, measurement input | 1.36 | 1.88 | [1] |
Measurement Input, Share Price [Member] | A2021 Warrants [Member] | |||
Warrant, measurement input | 1.36 | 2.5 | |
Measurement Input, Share Price [Member] | June 2020 Investor Warrants [Member] | |||
Warrant, measurement input | 1.36 | 2.5 | |
Measurement Input, Share Price [Member] | June 2020 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 1.36 | 2.5 | |
Measurement Input, Share Price [Member] | December 2019 Warrants [Member] | |||
Warrant, measurement input | 1.36 | 2.5 | |
Measurement Input, Share Price [Member] | December 2019 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 1.36 | 2.5 | |
Measurement Input, Conversion Price [Member] | May 2019 Warrants [Member] | |||
Warrant, measurement input | 1.55 | 3.52 | |
Measurement Input, Conversion Price [Member] | A2021 Warrants [Member] | |||
Warrant, measurement input | 12.81 | 12.81 | |
Measurement Input, Conversion Price [Member] | June 2020 Investor Warrants [Member] | |||
Warrant, measurement input | 5.18 | 5.18 | |
Measurement Input, Conversion Price [Member] | June 2020 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 5.64 | 5.64 | |
Measurement Input, Conversion Price [Member] | December 2019 Warrants [Member] | |||
Warrant, measurement input | 8.1 | 8.1 | |
Measurement Input, Conversion Price [Member] | December 2019 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 8.44 | 8.44 | |
Measurement Input, Risk Free Interest Rate [Member] | May 2019 Warrants [Member] | |||
Warrant, measurement input | 0.0548 | 0.053 | |
Measurement Input, Risk Free Interest Rate [Member] | A2021 Warrants [Member] | |||
Warrant, measurement input | 0.0465 | 0.042 | |
Measurement Input, Risk Free Interest Rate [Member] | June 2020 Investor Warrants [Member] | |||
Warrant, measurement input | 0.0473 | 0.0426 | |
Measurement Input, Risk Free Interest Rate [Member] | June 2020 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 0.0495 | 0.0454 | |
Measurement Input, Risk Free Interest Rate [Member] | December 2019 Warrants [Member] | |||
Warrant, measurement input | 0.0493 | 0.0453 | |
Measurement Input, Risk Free Interest Rate [Member] | December 2019 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 0.0523 | 0.0482 | |
Measurement Input, Expected Term [Member] | May 2019 Warrants [Member] | |||
Warrant, measurement input | 0.1 | 0.4 | |
Measurement Input, Expected Term [Member] | A2021 Warrants [Member] | |||
Warrant, measurement input | 1.86 | 2.11 | |
Measurement Input, Expected Term [Member] | June 2020 Investor Warrants [Member] | |||
Warrant, measurement input | 1.69 | 1.94 | |
Measurement Input, Expected Term [Member] | June 2020 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 1.19 | 1.44 | |
Measurement Input, Expected Term [Member] | December 2019 Warrants [Member] | |||
Warrant, measurement input | 1.22 | 1.47 | |
Measurement Input, Expected Term [Member] | December 2019 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 0.72 | 0.97 | |
Measurement Input, Price Volatility [Member] | May 2019 Warrants [Member] | |||
Warrant, measurement input | 0.922 | 0.775 | |
Measurement Input, Price Volatility [Member] | A2021 Warrants [Member] | |||
Warrant, measurement input | 0.942 | 0.765 | |
Measurement Input, Price Volatility [Member] | June 2020 Investor Warrants [Member] | |||
Warrant, measurement input | 0.954 | 0.782 | |
Measurement Input, Price Volatility [Member] | June 2020 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 1.021 | 0.83 | |
Measurement Input, Price Volatility [Member] | December 2019 Warrants [Member] | |||
Warrant, measurement input | 1.013 | 0.823 | |
Measurement Input, Price Volatility [Member] | December 2019 Placement Agent Warrants [Member] | |||
Warrant, measurement input | 1.234 | 0.852 | |
[1]As of December 31, 2023, management determined that a financing event was likely in the first quarter of 2024, and reduced the share price used in the model by 25% in order to reflect the total amount that would be realized accordingly. |
Note 12 - Stock-based Compens_3
Note 12 - Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 0 | ||
Stock Issued During Period, Value, Employee Benefit Plan | $ 237 | ||
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 50% | ||
Common Stock Contribution | $ 29 | $ 93 | |
Additional Paid-in Capital [Member] | |||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 163 | 0 | |
Stock Issued During Period, Value, Employee Benefit Plan | $ 237 | ||
Restricted Stock Units (RSUs) [Member] | |||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 1,007 | ||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 3 months 18 days |
Note 12 - Stock-based Compens_4
Note 12 - Stock-based Compensation - Stock Option Outstanding (Details) - Equity Incentive Plan 2014 [Member] $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) $ / shares shares | |
Balance (in shares) | shares | 252 |
Balance (in dollars per share) | $ / shares | $ 36.17 |
Options cancelled (in shares) | shares | (55) |
Options cancelled (in dollars per share) | $ / shares | $ 37.54 |
Balance (in shares) | shares | 197 |
Balance (in dollars per share) | $ / shares | $ 37.79 |
Balance as of March 31, 2024 (Year) | 4 years 3 months 3 days |
Balance as of March 31, 2024 | $ | $ 0 |
Vested and expected to vest as of March 31, 2024 (in shares) | shares | 197 |
Vested and expected to vest as of March 31, 2024 (in dollars per share) | $ / shares | $ 37.79 |
Vested and expected to vest as of March 31, 2024 (Year) | 4 years 3 months 3 days |
Vested and expected to vest as of March 31, 2024 | $ | $ 0 |
Exercisable as of March 31, 2024 (in shares) | shares | 196 |
Exercisable as of March 31, 2024 (in dollars per share) | $ / shares | $ 37.8 |
Exercisable as of March 31, 2024 (Year) | 4 years 3 months 3 days |
Exercisable as of March 31, 2024 | $ | $ 0 |
Note 12 - Stock-based Compens_5
Note 12 - Stock-based Compensation - RSU and PSU Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
Balance (in shares) | shares | 1,305 |
Balance (in dollars per share) | $ / shares | $ 1.67 |
Vested (in shares) | shares | (172) |
Vested (in dollars per share) | $ / shares | $ 1.87 |
Balance (in shares) | shares | 1,133 |
Balance (in dollars per share) | $ / shares | $ 1.64 |
Note 12 - Stock-based Compens_6
Note 12 - Stock-based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Stock based compensation | $ 376 | $ 424 |
Selling and Marketing Expense [Member] | ||
Stock based compensation | 52 | 64 |
Research and Development Expense [Member] | ||
Stock based compensation | 91 | 82 |
General and Administrative Expense [Member] | ||
Stock based compensation | $ 233 | $ 278 |
Note 14 - Commitments and Con_2
Note 14 - Commitments and Contingencies (Details Textual) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | 15 Months Ended | ||
Mar. 01, 2022 USD ($) | Oct. 15, 2012 USD ($) | Mar. 31, 2024 USD ($) | Jun. 30, 2023 | Dec. 31, 2023 USD ($) | Mar. 31, 2024 USD ($) | |
Number Of License Agreements | 2 | 2 | ||||
Other Research and Development Expense | $ 20 | |||||
Purchase Obligation | $ 2,387 | $ 2,783 | $ 2,387 | |||
Long-Term Purchase Commitment, Period (Year) | 1 year | |||||
Lessee, Operating Lease, Liability, to be Paid | $ 1,106 | $ 1,106 | ||||
San Rafael and Hamburg [Member] | ||||||
Lessee, Operating Lease, Term of Contract (Year) | 32 years | 32 years | ||||
Royalty Agreement Terms [Member] | ||||||
Royalty Percentage | 3.75% | |||||
Royalty Expense | $ 75 | $ 250 | $ 100 | |||
Royalty Agreement Terms [Member] | Licensed Patent Products [Member] | ||||||
Royalty Percentage | 6% | |||||
Royalty Agreement Terms [Member] | Licensed Software Products [Member] | ||||||
Royalty Percentage | 3% | |||||
Access to Information Technology Systems and Shared Services [Member] | ||||||
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Monthly Payments, Beyond Twelve Months | $ 3 | |||||
Sales Revenue Goods Net Excluding Government Sales [Member] | Royalty Agreement Terms [Member] | ||||||
Royalty Percentage | 1% | |||||
License Revenue [Member] | Royalty Agreement Terms [Member] | ||||||
Royalty Percentage | 21% |
Note 15 - Net Loss Per Share -
Note 15 - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Net loss applicable to common stockholders, basic and diluted | $ (3,429) | $ (4,389) |
Weighted-average number of shares, basic and diluted (in shares) | 17,419 | 13,296 |
Net loss per share, basic and diluted (in dollars per share) | $ (0.2) | $ (0.33) |
Note 15 - Net Loss Per Share _2
Note 15 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Antidilutive Securities (in shares) | 2,570 | 2,537 |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities (in shares) | 197 | 268 |
Restricted Stock [Member] | ||
Antidilutive Securities (in shares) | 1,133 | 1,029 |
Warrant [Member] | ||
Antidilutive Securities (in shares) | 1,240 | 1,240 |
Note 16 - Segment Disclosures_2
Note 16 - Segment Disclosures (Details Textual) | 3 Months Ended |
Mar. 31, 2024 | |
Number of Reportable Segments | 2 |
Note 16 - Segment Disclosures -
Note 16 - Segment Disclosures - Segment Reporting Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | $ 3,756 | $ 4,122 |
Cost of revenue | 1,805 | 2,122 |
Gross profit | 1,951 | 2,000 |
Ekso Health [Member] | ||
Revenue | 3,559 | 3,997 |
Cost of revenue | 1,655 | 1,951 |
Gross profit | 1,904 | 2,046 |
Ekso Works [Member] | ||
Revenue | 197 | 125 |
Cost of revenue | 150 | 171 |
Gross profit | $ 47 | $ (46) |
Note 16 - Segment Disclosures_3
Note 16 - Segment Disclosures - Geographic Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | $ 3,756 | $ 4,122 |
UNITED STATES | ||
Revenue | 2,297 | 2,958 |
Americas Other [Member] | ||
Revenue | 32 | 4 |
Americas [Member] | ||
Revenue | 2,329 | 2,962 |
FRANCE | ||
Revenue | 346 | 0 |
GERMANY | ||
Revenue | 124 | 244 |
EMEA Other [Member] | ||
Revenue | 360 | 512 |
EMEA [Member] | ||
Revenue | 830 | 756 |
INDONESIA | ||
Revenue | 336 | 0 |
APAC Other [Member] | ||
Revenue | 261 | 404 |
Asia Pacific [Member] | ||
Revenue | $ 597 | $ 404 |
Note 17 - Related Party Trans_2
Note 17 - Related Party Transactions (Details Textual) - Angel Pond Capital LLC [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Related Party Transaction, Amounts of Transaction | $ 325 | |
Related Party Transaction, Payment Term (Year) | 14 years | |
Accounts Payable | $ 15 | $ 60 |
Initial Payment1 [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 145 | |
Related Party Transaction, Payment Term (Year) | 40 months | |
Initial Payment [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 15 | |
Initial Payment2 [Member] | ||
Related Party Transaction, Payment Term (Year) | 12 years |